A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 20, 2016

Primary Completion Date

June 15, 2022

Study Completion Date

August 20, 2027

Conditions
Mantle Cell Lymphoma (MCL)
Interventions
DRUG

Acalabrutinib in combination with BR

DRUG

Acalabrutinib in combination with VR

Trial Locations (15)

11042

Research Site, Lake Success

37203

Research Site, Nashville

40138

Research Site, Bologna

40207

Research Site, Louisville

43210

Research Site, Columbus

48109

Research Site, Ann Arbor

77030

Research Site, Houston

98109

Research Site, Seattle

98122

Research Site, Seattle

07601

Research Site, Hackensack

07960

Research Site, Morristown

30-510

Research Site, Krakow

93-510

Research Site, Lodz

10-228

Research Site, Olsztyn

02-106

Research Site, Warsaw

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY